Navigation Links
Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
Date:9/18/2007

TOKYO, September 18 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that AD 337, an enantiomer of an approved, centrally acting, non-opioid, analgesic, has completed a Phase II proof of principle trial for the treatment of fibromyalgia syndrome (FMS).

The trial, a multi-centre, randomised, double-blind, placebo controlled, parallel group exploratory study, investigated the efficacy, safety and tolerability of AD 337 in the treatment of fibromyalgia in female subjects. In total, the trial enrolled 103 patients across 18 centres in the UK and Australia with the primary study endpoint being the difference in the Fibromyalgia Impact Questionnaire (FIQ) score, between active and placebo, after 4 weeks of treatment.

Results show that the study did not achieve a statistically significant outcome in its primary endpoint at 4 weeks. However statistical significance in FIQ was achieved at the 1 week time point and positive trends were seen throughout the study. In addition statistically significant measures in other efficacy assessments such as the Short Form McGill Pain Questionnaire and the Fibromyalgia Health Assessment Questionnaire (FHAQ) were seen at early time points. On balance it is concluded that AD 337 has some potential in the treatment of fibromyalgia syndrome.

AD 337 was well tolerated and there were no clinically significant changes in vital signs, biochemistry, haematology and cardiovascular parameters.

Commenting on these results Shinichi Tamura, CEO, said "This proof of principle study with an unoptimised formulation and dosing schedule and limited to four weeks in duration has demonstrated a degree of activity. Sosei will be evaluating these results to determine its approach to the possible further development of AD 337 in FMS and other potential indications."

Notes to Editors:

About Sosei

Sosei Group Corporation is a leading
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009).../--Shireplc(LSE:SHP,NASDAQ: SHPGY ),theglobalspec...thassubmittedaMAAtotheEuropeanMedicinesAgencyfor,v...apyindevelopment,forthetreatmentofType1Gaucherdise...erasealfathathasbeensubmitted,withprevious,submiss...balsupplyshortageofthecurrentlyapprovedandmarketed...
(Date:11/24/2009)...tomers with Partners Validated to Process and Anal... Ottawa, ON (PRWEB) Novemb...f products for biological sample collection, stabi...global partner program. The program offers signifi...ity and is designed to help partners scale and dif...
(Date:11/23/2009)...ami very high-tech origami. , Researchers at the... for fabricating three-dimensional, single-crystal...g photolithography and a self-folding process driv... few microns thick, offer mechanical bendability t...e material. , "This is a completely different app...
(Date:11/23/2009)...Call/-YMBioSciencesInc.(NYSEAmex: YMI ;TSX:YM),ali...ndadvancesadiverseportfolioofpromisingcancer-relat...edthatCytopia(ASX:CYT)hascommencedenrollmentofaPha...teredJAK1/JAK2inhibitor.Thetrialisbeingconductedat...topiaintoYMhasbeenpreviouslyannouncedandispendinga...
Breaking Biology Technology:Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Water droplets direct self-assembly process in thin-film materials 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4
...d publications used to uphold a challenge to its s...nd proliferation of human embryonic stem cells, th... a response refuting an initial determination by...observations on relevancy, made by Carl Gulbrandse...r. Colin Stewart , a stem cell researcher at the I...
...in improperly apply its five percent sales tax to ... ,The Wisconsin Supreme Court will decide that q... and there is an estimated $350 million at stake f...,000 for Menasha Corp. , ,At issue is the definiti...f software is not subject to the state sales tax. ...
...r who built and rebuilt technology-based companies... Day award, which will be presented June 13 at the...e. , ,Eddy, who has overcome business and personal...e award and speak during a conference luncheon at ... involved in the technology industry for more than...
Other Biology Technology:WARF questions relevancy of documents used to uphold patent challenge 2WARF questions relevancy of documents used to uphold patent challenge 3
(Date:11/23/2009)...ed strain of the deadly superbug MRSAan infection-...icsposes a far greater health threat than previous...ording to a study in the December issue of Emergi...sily picked up in fitness centers, schools, and ot...rden of MRSA within hospitals, the report found. ,...
(Date:11/23/2009)...of day matters to forest trees dealing with drough... team led by Professor Malcolm Campbell, Universit...arch and colleagues in the department of cell and ...pitalizing on their previous work to decode the ge...d how poplar trees use their 45,000 genes to respo...
(Date:11/23/2009)...ants gathered this week for the seventh annual Nat.... This year,s topic, "Synthetic Biology," brought ...chers to explore the engineering, scientific, and ...nthetic biology. , Bonnie L. Bassler, professor ...his year,s conference chair, challenged the attend...
Breaking Biology News(10 mins):New study finds MRSA on the rise in hospital outpatients 2Time of day matters to thirsty trees, U of T researcher discovers 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Study Shows 1 25 of Americans Have Been Infected With West Nile 56658 1Study Shows 1 25 of Americans Have Been Infected With West Nile 56658 2Study Shows 1 25 of Americans Have Been Infected With West Nile 56658 3IBM Study Reveals Drug Companies Struggle to Improve Supply Chain to Battle Counterfeiting Safety Concerns and Global Complexity 56655 1IBM Study Reveals Drug Companies Struggle to Improve Supply Chain to Battle Counterfeiting Safety Concerns and Global Complexity 56655 2IBM Study Reveals Drug Companies Struggle to Improve Supply Chain to Battle Counterfeiting Safety Concerns and Global Complexity 56655 3IBM Study Reveals Drug Companies Struggle to Improve Supply Chain to Battle Counterfeiting Safety Concerns and Global Complexity 56655 4Kool Smiles Joins Governor OMalley to Announce New Healthy Smiles Tour 56652 1Kool Smiles Joins Governor OMalley to Announce New Healthy Smiles Tour 56652 2Kool Smiles Joins Governor OMalley to Announce New Healthy Smiles Tour 56652 3
...National Institute of Child Health and Development...awarded Albert Einstein College of Medicine of Yes...a Specialized Cooperative Center Program in Reprod...ly 13 such centers in the country and the only one... wide range of diseases of the female reproductive...
...ty] People have always been fascinated by bats, b... to how bats fly and their bizarre habit of sleepi...bats arrive at their daytime perches. , A Brown U...nt the landing approaches of three species of bats...ees. What they found was surprising: Not all bats ...
...mshoe. The University of Alberta medical geneticis...glaucoma. , Glaucoma is a leading cause of blindne...ng the brain from understanding what patients see....36 and glaucoma, but have been unable to figure ou...ations of the gene get glaucoma while others don,t...
Other Biology News:NIH funds research center for women's reproductive health at Einstein 2NIH funds research center for women's reproductive health at Einstein 3Brown-led team offers first look at how bats land 2Brown-led team offers first look at how bats land 3Genetic sleuth solves glaucoma mystery 2
...tinal (CIAP), catalyzes the hydrolysis of 5-phosph...ucleoside triphosphates. This enzyme is used to pr...ed cloning vector DNA by removing phosphate groups...dephosphorylation of 5 phosphorylated ends of DNA ...
ELISA Plate Sealers, 100 Pack from R&D Systems
Rat Anti-Mouse P-Selectin / CD62P Monoclonal Antibody, Unconjugated, Clone 127933 from R&D Systems
Mouse Anti-Mouse IgD Chain C Monoclonal Antibody, Unconjugated, Clone AMS 9.1 from Santa Cruz Biotechnology, Inc.
Biology Products: